A carregar...
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation. Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a...
Na minha lista:
| Publicado no: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5572324/ https://ncbi.nlm.nih.gov/pubmed/28878676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00561 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|